- Results of Phase 1 clinical studies support advancement to Phase 2 - - Results of in-vitro study of ITMN-191 with Roche polymerase inhibitors -
BRISBANE, Calif., Sept. 24 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that four abstracts from clinical and in-vitro studies of ITMN-191 (R7227) accepted for presentation at the 59th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD, Oct. 31 - Nov. 4 in San Francisco), may now be viewed at http://www.aasld.org. ITMN-191 is a hepatitis C virus (HCV) NS3 protease inhibitor, currently in a Phase 1b clinical trial in combination with Pegasys(R) (peginterferon alfa-2a) and Copegus(R) (ribavirin). The compound is being developed in collaboration with Roche.
Dan Welch, Chairman, Chief Executive Officer and President of InterMune, said, "Collectively, these abstracts demonstrate that in the experiments conducted, ITMN-191 was safe and very well tolerated in humans and demonstrated viral kinetics that are competitive with other direct anti-viral compounds in development. The safety and viral kinetic profile of ITMN-191 was observed in mono-therapy regimens administered twice-a-day and three-times-a-day in both treatment-naive patients and in patients who had failed to adequately respond to standard-of-care treatment. Additionally, results from in-vitro experiments of the antiviral effect of ITMN-191 in combination with two separate HCV polymerase inhibitors in the Roche portfolio suggest the potential benefit of treatment regimens that simultaneously target the HCV protease and polymerase."
Results of Two Clinical Studies of ITMN-191
-- A Phase 1a Single-Ascending-Dos
|SOURCE InterMune, Inc.|
Copyright©2008 PR Newswire.
All rights reserved